Jones Financial Companies
BTAI icon

Jones Financial Companies’s BioXcel Therapeutics BTAI Stock Holding History

Jones Financial Companies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Sell
131,789
-5,901
-4% -$9.72K ﹤0.01% 2463
2025
Q4 		$220K Buy
137,690
+101,690
+282% +$210K ﹤0.01% 1867
2025
Q3 		$97.2K Buy
36,000
+10,000
+38% +$31.5K ﹤0.01% 2103
2025
Q2 		$46K Buy
+26,000
New +$43K ﹤0.01% 2254

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jones Financial Companies's BTAI Position: Q1 2026 in Review

Jones Financial Companies reduced its BioXcel Therapeutics (BTAI) stake by 4.3% in Q1 2026, selling an estimated $9.72K and leaving 131,789 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #2463.

Jones Financial Companies first reported a position in BTAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $220K in Q4 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Jones Financial Companies held 131,789 shares of BioXcel Therapeutics worth $166K as of Q1 2026.
  • Jones Financial Companies sold 5,901 BioXcel Therapeutics shares in Q1 2026, an estimated $9.72K.
  • BioXcel Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #2463 holding.
  • Jones Financial Companies first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's BioXcel Therapeutics position peaked at $220K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.